KD-414

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 20221.

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1301281576 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “KD-414” revision 1301281576 · retrieved 2026-10-20 release date (×1) · confidence 0.95 revision URL